Breaking News Instant updates and real-time market news.

SPHS

Sophiris Bio

$3.07

0.5 (19.46%)

09:45
08/29/18
08/29
09:45
08/29/18
09:45

Sophiris Bio price target raised to $10 from $4.30 at H.C. Wainwright

H.C. Wainwright analyst Joseph Pantginis raised his price target for Sophiris Bio to $10 after the company and investigators found that the death of a patient is unlikely to have been related to either topsalysin or the procedure. Today's information allows focus to return to the underlying investment case on Sophiris, subsequent to the positive Phase 2b data announced on June 25, Pantginis tells investors in a research note. The analyst reiterates a Buy rating on Sophiris Bio.

SPHS Sophiris Bio
$3.07

0.5 (19.46%)

06/25/18
PIPR
06/25/18
NO CHANGE
Target $7
PIPR
Overweight
Piper says Sophiris Bio 'worth sticking with' despite patient death in trial
A patient death after retreatment has "placed a cloud" over Sophiris Bio's topsalysin program despite efficacy data that was "clearly a home run," according to Piper Jaffray analyst Christopher Raymond. He sees a good chance the incident may end up not being categorized as drug-related, noting that topsalysin previously had shown a "pristine safety profile," and Raymond thinks the stock is "worth sticking with" at this point. The analyst, who is reserving judgment until more detail on topsalysin's role in the death is available, thinks there remains a credible path forward even if the death is deemed drug related. He keeps an Overweight rating and $7 price target on Sophiris shares, which fell about 40% to $2.24 today.
06/26/18
PIPR
06/26/18
NO CHANGE
Target $7
PIPR
Overweight
Sophiris Bio 'worth sticking with' after patient death, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond maintained an Overweight rating and $7 price target on Sophiris Bio following disclosure of Phase 2b topsalysin data in localized prostate cancer. In a research note to investors, Raymond contended that while a patient death is "never a great headline," and that death after retreatment has now placed a cloud over the program, he thinks there is a good chance this incident may end up not being categorized as drug-related, and thinks it's worth "sticking with it here." Raymond sees a "credible" path forward with single administration, and urges investors to be patient on the name as clarity on the death and clinical path come more into focus.
08/14/18
PIPR
08/14/18
NO CHANGE
Target $7
PIPR
Overweight
Sophiris Bio topsalycin trial death disclosure imminent, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond kept his Overweight rating and $7 price target on Sophiris Bio after its "uneventful" Q2 report. The analyst says that while the company did not update on the cause of death of one of its Phase 2b topsalycin trial patients, conversations with the management suggest that the disclosure is "imminent". Raymond adds that with the cause of death being announced, the "cloud" over the program will be lifted, allowing investors to focus on the drug's "impressive efficacy".
08/29/18
PIPR
08/29/18
NO CHANGE
Target $7
PIPR
Overweight
Piper expects shares of Sophiris Bio to open 'sharply higher'
Piper Jaffray analyst Christopher Raymond expects shares of Sophiris Bio to open "sharply higher" on this morning's formal confirmation that topsalysin was not a factor in a patient death seen in the drug's Phase 2b study in patients with localized prostate cancer. In that the death "cast a pall over an otherwise positive data release, we expect the stock to react favorably this morning," Raymond tells investors in a research note. He points out that moving forward, Sophiris has indicated a Phase 3 study confirming the clinical response rate is planned likely next year. The analyst likes the set-up for topsalysin and keeps an Overweight rating on Sophiris Bio with a $7 price target. The stock in premarket trading is up 23%, or 58c, to $3.14.

TODAY'S FREE FLY STORIES

SHPG

Shire

$169.68

-0.44 (-0.26%)

, TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

07:20
12/12/18
12/12
07:20
12/12/18
07:20
Downgrade
Shire, Takeda Pharmaceutical rating change  »

Shire downgraded to Hold…

SHPG

Shire

$169.68

-0.44 (-0.26%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 21

    Dec

  • 11

    Jan

07:20
12/12/18
12/12
07:20
12/12/18
07:20
General news
FX Update: The dollar has been trading mixed-to-firmer »

FX Update: The dollar has…

07:17
12/12/18
12/12
07:17
12/12/18
07:17
General news
Futures higher following release of Huawei CFO »

Stock futures are…

CORT

Corcept Therapeutics

$17.16

4.18 (32.20%)

07:17
12/12/18
12/12
07:17
12/12/18
07:17
Upgrade
Corcept Therapeutics rating change  »

Cantor upgrades Corcept…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DCO

Ducommun

$38.00

0.2 (0.53%)

07:13
12/12/18
12/12
07:13
12/12/18
07:13
Initiation
Ducommun initiated  »

Ducommun initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSDT

Helius Medical

$9.94

-0.33 (-3.21%)

07:12
12/12/18
12/12
07:12
12/12/18
07:12
Hot Stocks
Helius Medical announces PoNS application for CE Mark »

Helius Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITCI

Intra-Cellular

$15.50

0.16 (1.04%)

07:12
12/12/18
12/12
07:12
12/12/18
07:12
Recommendations
Intra-Cellular analyst commentary  »

Intra-Cellular's NDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

MNGPY

Man Group

$0.00

(0.00%)

07:11
12/12/18
12/12
07:11
12/12/18
07:11
Downgrade
Man Group rating change  »

Man Group downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCY

Oncolytics

$2.03

0.01 (0.50%)

, BMY

Bristol-Myers

$52.44

-0.15 (-0.29%)

07:10
12/12/18
12/12
07:10
12/12/18
07:10
Hot Stocks
Oncolytics treats first patient in pelareorep, carfilzomib with Opdivo trial »

Oncolytics (ONCY)…

ONCY

Oncolytics

$2.03

0.01 (0.50%)

BMY

Bristol-Myers

$52.44

-0.15 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 29

    Dec

  • 24

    Jan

  • 20

    May

UNIT

Uniti Group

$19.59

0.52 (2.73%)

07:10
12/12/18
12/12
07:10
12/12/18
07:10
Downgrade
Uniti Group rating change  »

Uniti Group downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$207.29

-0.545 (-0.26%)

07:09
12/12/18
12/12
07:09
12/12/18
07:09
Hot Stocks
Lennox sees $347M in insurance proceeds for 2018, 2019 »

Overall for 2018 and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

SRNE

Sorrento Therapeutics

$2.66

-0.27 (-9.22%)

07:08
12/12/18
12/12
07:08
12/12/18
07:08
Recommendations
Sorrento Therapeutics analyst commentary  »

Sorrento Therapeutics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDR

McDermott

$7.28

-0.37 (-4.84%)

, GE

General Electric

$6.77

-0.15 (-2.17%)

07:08
12/12/18
12/12
07:08
12/12/18
07:08
Hot Stocks
McDermott, Baker Hughes, selected for Equus Gas Project in Australia »

McDermott (MDR), with…

MDR

McDermott

$7.28

-0.37 (-4.84%)

GE

General Electric

$6.77

-0.15 (-2.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOH

Molina Healthcare

$135.79

2.32 (1.74%)

07:08
12/12/18
12/12
07:08
12/12/18
07:08
Hot Stocks
Molina Healthcare awarded CHIP contract in Mississippi »

Molina Healthcare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVEO

Aveo Pharmaceuticals

$2.03

0.01 (0.50%)

, AZN

AstraZeneca

$38.63

0.22 (0.57%)

07:08
12/12/18
12/12
07:08
12/12/18
07:08
Hot Stocks
Aveo Oncology announces immuno-oncology clinical collaboration with AstraZeneca »

AVEO Oncology (AVEO)…

AVEO

Aveo Pharmaceuticals

$2.03

0.01 (0.50%)

AZN

AstraZeneca

$38.63

0.22 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRMN

Garmin

$65.37

0.41 (0.63%)

07:08
12/12/18
12/12
07:08
12/12/18
07:08
Hot Stocks
Garmin Health, ActiGraph collaborate on wearable solutions for clinical trials »

Garmin International, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

BIOS

BioScrip

$3.84

0.1 (2.67%)

07:08
12/12/18
12/12
07:08
12/12/18
07:08
Initiation
BioScrip initiated  »

BioScrip initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$207.29

-0.545 (-0.26%)

07:07
12/12/18
12/12
07:07
12/12/18
07:07
Hot Stocks
Lennox sees FY18 CapEx approximately $125M »

Including $25M in 2018…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

APHA

Aphria

$6.14

0.55 (9.84%)

07:06
12/12/18
12/12
07:06
12/12/18
07:06
Hot Stocks
Aphria signs letter of intent to supply medical cannabis in Paraguay »

Aphria has signed a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SKIS

Peak Resorts

$4.98

-0.01 (-0.20%)

07:06
12/12/18
12/12
07:06
12/12/18
07:06
Earnings
Peak Resorts reports Q2 EPS (81c) vs. (66c) last year »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

AMRH

AMERI Holdings

$0.25

-0.0061 (-2.38%)

07:06
12/12/18
12/12
07:06
12/12/18
07:06
Hot Stocks
AMERI Holdings names founder Dev Nidhi as Executive Chairman »

AMERI Holdings announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$207.29

-0.545 (-0.26%)

07:05
12/12/18
12/12
07:05
12/12/18
07:05
Hot Stocks
Lennox sees FY19 CapEx approximately $215M »

Including $115M in 2019…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

07:05
12/12/18
12/12
07:05
12/12/18
07:05
General news
European stock markets are broadly higher »

European stock markets…

CRMD

CorMedix

$1.58

-0.08 (-4.82%)

07:04
12/12/18
12/12
07:04
12/12/18
07:04
Recommendations
CorMedix analyst commentary  »

CorMedix price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JBLU

JetBlue

$17.93

-0.02 (-0.11%)

07:04
12/12/18
12/12
07:04
12/12/18
07:04
Hot Stocks
Breaking Hot Stocks news story on JetBlue »

JetBlue sees Q4 RASM up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.